Finlay-Jones J J, Bartholomaeus W N, Fimmel P J, Keast D, Stanley N F
J Natl Cancer Inst. 1980 Jun;64(6):1363-72.
Some biologic, hematologic, and immunologic aspects of the growth and metastasis of the MC-2 fibrosarcoma indicated its suitability as a model for the study of lymphogenous metastasis. The tumor was maintained in syngeneic female BALB/c mice by the serial sc passage of 10(5) viable tumor cells. It metastasized macroscopically in all mice to regional lymph nodes (RLN) and to the lungs. Both forward and retrograde node-to-node metastases were found. Tumor growth and metastasis were associated with splenomegaly, thymus atrophy, cachexia, neutrophilia, lymphopenia, and anemia. Tumor excision at various times after inoculation showed that all mice whose tumors were excised when there was histologic evidence of metastasis in all RLN (day 13; mean of tumor wt, 122 mg) died subsequently from metastases, whereas no animals died whose tumors were excised on or before day 8 (mean of tumor wt, 15 mg). The onset of metastasis was seen in some RLN on day 8. All survivors were immune to challenge with 10(5) viable tumor cells, which demonstrated the immunogenicity of the tumor. Concomitant tumor immunity could be demonstrated prior to the onset of metastasis (days 6 and 7) but not early (days 0--2) or late (days 15, 19, and 20) in primary-site tumor growth. The early immune response to the tumor demonstrable as concomitant tumor immunity appeared to be abrogated by the progressive growth and metastasis of the neoplasm. Tumor cells passaged in adult thymectomized, X-irradiated, syngeneic recipients produced larger RLN metastases and smaller primary tumors than those passaged in control mice.
MC-2纤维肉瘤生长和转移的一些生物学、血液学及免疫学方面表明,它适合作为研究淋巴源性转移的模型。通过连续皮下传代10(5)个活肿瘤细胞,将该肿瘤维持在同基因雌性BALB/c小鼠体内。它在所有小鼠中均发生肉眼可见的转移,转移至区域淋巴结(RLN)和肺部。发现了正向和逆向的淋巴结间转移。肿瘤生长和转移与脾肿大、胸腺萎缩、恶病质、中性粒细胞增多、淋巴细胞减少及贫血有关。接种后不同时间切除肿瘤表明,所有在组织学证据显示所有RLN均有转移时(第13天;肿瘤重量平均值为122毫克)切除肿瘤的小鼠随后均死于转移,而在第8天或之前(肿瘤重量平均值为15毫克)切除肿瘤的动物无一死亡。在第8天,一些RLN出现转移。所有存活的动物对10(5)个活肿瘤细胞的攻击具有免疫力,这证明了肿瘤的免疫原性。在转移发生之前(第6天和第7天)可证明存在伴随肿瘤免疫,但在原发部位肿瘤生长的早期(第0 - 2天)或晚期(第15天、19天和20天)则未出现。随着肿瘤逐渐生长和转移,可证明的对肿瘤的早期免疫反应(即伴随肿瘤免疫)似乎被消除。与在对照小鼠中传代的肿瘤细胞相比,在成年胸腺切除、X射线照射的同基因受体中传代的肿瘤细胞产生更大的RLN转移灶和更小的原发肿瘤。